Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...

A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...

The diagnosis? Heart failure with only months to live. But Eric Borstein fought his way back. He shares his amazing journey ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

Prioritizing education and shared decision-making can help patients with newly diagnosed heart failure feel less overwhelmed, ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the ...

Among the most dangerous issues facing patients in need of replacement mechanical heart valves is aortic regurgitation —  a ...

The organisations will combine expertise with analytical technologies. The National Heart Centre Singapore and Agilent ...

Cardiac performance in patients with HF can be determined with measurement of the time for peak oxygen uptake to decrease by more than 12.5%.